Impact of preoperative CA19-9 and histology grade on prognosis of pancreatic ductal adenocarcinoma and its value in TNM stage-Reference-Cited by-同舟云学术

Impact of preoperative CA19-9 and histology grade on prognosis of pancreatic ductal adenocarcinoma and its value in TNM stage

Published:2023-03-23 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

Chang Shaofei¹,Liu Yaohua²,Liang Yuexiang¹,Man Quan¹,Li Haorui¹,Guo Yu¹,Zhao Tiansuo¹

Affiliation:

1. Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Tianjin’s Clinical Research Center For Cancer

2. Shanxi Provincial Second People’s Hospital

Abstract

Abstract Preoperative serum CA19-9 and histology grade could show the biological characteristics of pancreatic ductal adenocarcinoma (PDAC). This study aims to explore the combined effect of preoperative CA19-9 and histology grade on the prognosis of patients with PDAC. A total of 612 patients with PDAC undergoing curative pancreatectomy were retrospectively enrolled. 360 (58.8%) patients had preoperative CA19-9 > 112 U/ml and 348 (56.9%) patients had high histology grade. A biological risk model was established based on preoperative CA19-9 and histology grade. Prognostic analysis showed that biological risk based on preoperative CA19-9 and histology grade was independently associated with survival of PDAC patients. Then the biological risk was incorporated into the eighth edition of the TNM staging system and a modified TNM (mTNM) staging system was developed. The ROC curves showed that the area under curve(AUC) of the mTNM staging system was significantly greater than that of the TNM staging system. Biological risk based on preoperative CA19-9 and histology grade was an independent prognostic factor for patients with PDAC. Incorporating the biological risk into the TNM staging system could improve the the accuracy of the TNM staging system in predicting prognosis of patients with PDAC.

Publisher

Research Square Platform LLC

Reference34 articles.

1. Global Cancer Observatory (http://gco.iarc.fr/today/online-analysis-table) International Agency Research on Cancer 2022.

2. SEER 17 2012–2018, All Races, Both Sexes by SEER Combined Summary Stage. https://seer.cancer.gov/statfacts/html/pancreas.html

3. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®)Pancreatic Adenocarcinoma Version 1. 2022 - February 24,2022. https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.

4. Webber C, Gospodarowicz M, Sobin LH, Wittekind C, Greene FL, Mason MD, Compton C, Brierley J, Groome PA. Improving the TNM classification: findings from a 10-year continuous literature review. Int J Cancer. 2014 Jul 15;135(2):371-8. doi: 10.1002/ijc.28683. PMID: 24921087.

5. van Roessel S, Kasumova GG, Verheij J, Najarian RM, Maggino L, de Pastena M, Malleo G, Marchegiani G, Salvia R, Ng SC, de Geus SW, Lof S, Giovinazzo F, van Dam JL, Kent TS, Busch OR, van Eijck CH, Koerkamp BG, Abu Hilal M, Bassi C, Tseng JF, Besselink MG. International Validation of the Eighth Edition of the American Joint Committee on Cancer (AJCC) TNM Staging System in Patients With Resected Pancreatic Cancer. JAMA Surg. 2018 Dec 1;153(12):e183617. doi: 10.1001/jamasurg.2018.3617. Epub 2018 Dec 19. Erratum in: JAMA Surg. 2019 Feb 20;: PMID: 30285076; PMCID: PMC6583013.